Literature DB >> 15521065

Noonan syndrome type I with PTPN11 3 bp deletion: structure-function implications.

Wen Hwa Lee1, Annick Raas-Rotschild, Maria A Miteva, Giulia Bolasco, Azaria Rein, David Gillis, Dominique Vidaud, Michel Vidaud, Bruno O Villoutreix, Beatrice Parfait.   

Abstract

Noonan syndrome was recently reported to be caused by mutations in the PTPN11 gene in 40% of the cases. This gene encodes the nonreceptor-type protein tyrosine phosphatase SHP-2 and has been shown to be self down-regulated with the concurrency of two SH2 domains. Insertion of a specific loop (D'EF) from N-terminal SH2 domain into the SHP-2 active-site is responsible for the reversible inhibition of the phosphatase activity. Here we report the first in frame trinucleotide deletion resulting in the removal of Aspartate 61 (D61del), a key residue of the N-terminal SH2 D'EF loop. Energetic-based structural analysis and electrostatic calculations carried out on the wild-type and mutant proteins predict lower stability of the D'EF loop for the D61del variant as compared to the wild type indicating better access to the active site and most likely an enzyme activated for longer extent. Similar computations were performed on the previously functionally characterized gain-of-function D61Y mutant and similar behaviors were observed. The simulation data for the D61del and D61Y mutants suggest that both variants could yield more catalytic cycles than the wild-type molecule in the same timespan because of the opening of the active site. It also supports the notion that D61 plays a major role for proper down-regulation of the protein tyrosine phosphatase activity of SHP-2. (c) 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15521065     DOI: 10.1002/prot.20296

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  4 in total

1.  Diversity and functional consequences of germline and somatic PTPN11 mutations in human disease.

Authors:  Marco Tartaglia; Simone Martinelli; Lorenzo Stella; Gianfranco Bocchinfuso; Elisabetta Flex; Viviana Cordeddu; Giuseppe Zampino; Ineke van der Burgt; Antonio Palleschi; Tamara C Petrucci; Mariella Sorcini; Claudia Schoch; Robin Foa; Peter D Emanuel; Bruce D Gelb
Journal:  Am J Hum Genet       Date:  2005-12-07       Impact factor: 11.025

2.  Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations.

Authors:  Jeevana Praharsha Athota; Meenakshi Bhat; Sheela Nampoothiri; Kalpana Gowrishankar; Sanjeeva Ghanti Narayanachar; Vinuth Puttamallesh; Mohammed Oomer Farooque; Swathi Shetty
Journal:  BMC Med Genet       Date:  2020-03-12       Impact factor: 2.103

3.  Analyzing effects of naturally occurring missense mutations.

Authors:  Zhe Zhang; Maria A Miteva; Lin Wang; Emil Alexov
Journal:  Comput Math Methods Med       Date:  2012-04-22       Impact factor: 2.238

4.  Noonan Syndrome in South Africa: Clinical and Molecular Profiles.

Authors:  Cedrik Tekendo-Ngongang; Gloudi Agenbag; Christian Domilongo Bope; Alina Izabela Esterhuizen; Ambroise Wonkam
Journal:  Front Genet       Date:  2019-04-16       Impact factor: 4.599

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.